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INTRODUCTION 
The nature of respiratory pathogens is changing. In 
recent years there has been an increase in the incidence 
of infections caused by previously unrecognized 
organisms, such as Legionella, Chlamydia pneumoniae 
and Moraxella catarrhalis, and of other clinical isolates 
resistant to reference antibacterials. Identification of the 
etiologic agents of lower respiratory tract infections 
(LRTIs) in general practice is frequently retrospective 
and treatment is empirical. The distribution of bacteria 
responsible for community-acquired pneumonia (CAP) 
varies by location, season, home environment, and 
a myriad of other factors. Any estimate of pathogen 
distribution will, therefore, be approximate. As this 
paper is not intended to be an extensive review, only 
the major and most prevalent bacterial pathogens will 
be discussed. 
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MICROBIOLOGY 
Evaluation of patients presenting with RTIs includes 
diagnostic tests. The value of the oldest and most rapid 
test, the Gram stain, has been limited by the quality of 
the specimens collected. It remains, however, the least 
expensive, easiest and most rapid method to assist in the 
determination of the etiology of RTIs. 
Culture results, usually obtained 24 h after specimen 
collection, will confirm the findings of the Gram stain 
and enable determination of susceptibility to anti- 
bacterials. This is particularly crucial when the patient 
is not responding to treatment. More invasive diag- 
nostic techniques (fiberoptic bronchoscopy, broncheo- 
alveolar lavage or transthoracic pulmonary needle 
aspiration) will be performed only in cases of severe 
infection where the etiologic agent has not been 
identified and/or in patients not responding to therapy. 
A skilful laboratory is a prerequisite to the collection of 
such specimens. Blood cultures, which are positive in 
about 30% of patients with pneuniococcal pneumonia, 
are extremely useful and should always be done before 
starting treatment. 
All these techniques will enable diagnosis to be 
made in 30-50% of episodes. An additional 25% can 
be diagnosed by serologic tests (immunofluorescence, 
imniunoenzymatic tests) for Legionella, Mycoplasrna 
pneumoniae, Chlamydia pneurnoniae or Coxiella brirnetii 
and by antigen detection, e.g. by gene amplification. In 
immunocompromised patients with various infections, 
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viral cultures and other diagnostic procedures are 
necessary. 
The major drawbacks of serologic tests are cost and 
time (it takes at least 7-9 days for the tests to become 
positive). Consequently, the use of serology in the 
initial evaluation ofpatients is not useful but it is helpful 
€or retrospective evaluation. Despite the widespread 
availability of sophisticated diagnostic techniques, 
roughly 50% of episodes remain unidentified [l]. 
Performance of serologic tests and adequate culture 
procedures, in addition to the assessment of patient 
characteristics, underlying diseases, geographic location 
and season, may explain the wide range in incidence 
rates for respiratory pathogens in CAP. 
EPIDEMIOLOGY 
Community-acquired pneumonia 
CAP continues to be a problem because of changes in 
its clinical and epidemiologic characteristics and its 
association with mortality rates ranging from 2-21% 
[2]. Prior inappropriate antibiotic treatment has been 
found to be significantly related to a poor clinical 
course [3]. The etiology is a source of controversy, with 
incidence rates of 0-21% for Legionella and 0.5-75% 
€or Streptococcus pneumoniae in CAP. The incidence 
rates of pneumococcal pneumonia vary between 46% 
(Sweden) and 8% (Canada) and might be related to 
patient characteristics, epidemiologic factors or the 
diagnostic use of pneumococcal polysaccharide capsular 
antigen in some studies but not in others [4]. Strepto- 
coccus pneumoniae, and microorganisms associated with 
atypical pneumonia (Mycoplasma pneumoniae, Chlamydia 
pneumoniae, Legionella pneumophila), have been identified 
as the most common cause of CAP in patients who 
do not have a previous history of aspiration or the 
underlying risk factors for either tracheobronchial 
colonization by Haemophilus injuenzae or RTIs caused 
by aerobic Gram-negative bacilli. 
Acquired resistance of Streptococcus pneumoniae to 
p-lactams and other antibacterials represents a thera- 
peutic challenge and emphasizes the need for alter- 
native drugs, especially when oral administration is 
feasible. Resistance rates of Streptococcus pneumoniae to 
penicillin and erythromycin vary between 2-45% and 
10-23% in western Europe and the USA, respectively 
WI. 
Chlamydia pneumoniae is responsible for 6-34% 
of cases of CAP [7]. The proportion of pneumonia 
due to H .  intuenzae ranges between 8% and 20% 
[8,9]. Approximately 10% of cases of CAP in endemic 
periods and up to 50% in epidemic periods are 
caused by Mycoplasma pneumoniae [lo]. Streptococcus 
pyogenes and other streptococci rarely cause pneumonia. 
Lancefield group B streptococci are important etiologic 
agents in neonates and have caused rare cases in adults 
[ l l ] .  Two studies have questioned the role of Klebsiella 
pneumoniae as a cause of CAP [12,13]. Moraxella 
catarrhalis is responsible for a very small percentage 
(-1%) of cases of CAP [14]. Psittacosis and Coxiella 
burnetii pneumonia are unusual infections and may 
occur in epidemics. The differences in incidence rates 
may be due to patient characteristics, and emphasize 
the need to investigate epidemiologic factors specific to 
different regions in order to provide the major basis for 
the choice of initial empirical treatment. 
Acute exacerbation of chronic bronchitis (AECB) 
Non-typeable H. infuenzae is the most common 
pathogen implicated in purulent AECB, followed 
by Streptococcus pneumoniae, and Moraxella catarrhalis 
has been isolated with increasing fiequency [ 151. Often 
they are associated as copathogens. Mycoplasma pneu- 
moniae also seems to be a frequent cause of acute 
respiratory infections in patients with chronic bronchtis 
[16]. These data emphasize the need for drugs with a 
wider spectrum than that of p-lactams. 
Acute maxillary sinusitis 
The endogenous bacterial flora of the adult nose are 
composed of Staphylococcus aureus (25-40%) in the 
nasal vestibule, and Streptococcus pneumoniae (15-25%), 
H. inztrenzae (6-40%), Streptococcus pyogenes (6%) and 
Staphylococcus aureus (12%) in the posterior naso- 
pharynx. Acute maxillary sinusitis usually complicates 
common colds or other viral infections of the upper 
respiratory tract. Streptococcus pneumoniae and non- 
encapsulated strains of H. intuenzae are the most 
frequently isolated pathogens in community-acquired 
sinusitis, although Moraxella catarrhalis is being recovered 
with increasing fiequency (Table 1). Streptococcus pyogenes, 
Staphylococcus aureus and other Gram-negative bacilli are 
occasional pathogens, and chronic sinusitis caused by 
anaerobic bacteria, with or without aerobes, tends to 
Table 1 Acute sinusitis in adults: percentage incidence of 
respiratory pathogens 
% 
Streptococcus pneumoriiae 
H .  infuenzae 
Streptococcus pnenmoriiae + H. influenzae 
Anaerobic bacteria 
Moraxella catarrhah 
Streptococcus pyogenes 
Other streptococcal spp. 
Staphylococcus aureur 
20-41 
6-50 
1-9 
0-10 
2-4 
1-8 
2 
0-8 
Puncture aspirate of the maxillary antrum. Adapted from Gwaltney 
et a1 [17]. 
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occur in patients with dental diseases. Mycoplasma spp. 
have not been implicated in acute sinusitis and are an 
unlikely cause of disease. Chlamydia pneurnoniae is a 
more likely candidate, but is not a proven cause at 
this time. As aspiration of the sinuses is not undertaken 
routinely, antibiotics are almost always given empirically. 
Acute otitis media (AOM) 
The bacteriology of AOM has been studied extensively 
but mostly in children. Although some minor variations 
exist, Streptococcus pneumoniae is still the most common 
single isolate. Its contribution to the etiology of AOM 
has fallen substantially from 10-20 years ago, when 
approximately two-thirds of AOM episodes were due 
to pneumococci. Currently, Streptococcus pneumoniae is 
found in 39% of AOM patients, on average, and 
H .  infuenzae accounts for about 27% of cases; 90%) 
are non-typeable and 10% are type b. The third most 
common pathogen is now Moraxella catarrhalis, which is 
found in about 10% of cases. 
Group A streptococci have been isolated less 
frequently in recent years and now account for only 
3% of middle ear infections. The overall contribution 
of Streptococcus p y c p t e s  to the etiology of AOM varies 
with the season. In mid-winter, Streptococcus pyogenes 
can represent up to 10% ofisolates. This microorganism 
has frequently been isolated in Scandinavian countries 
andJapan. Staphylococcus aureus (2%) and Gram-negative 
bacilli are less common pathogens. Infections with 
more than one pathogen can occur, the most frequent 
combination being Streptococcus pneumoniae and H .  
ip$iienzae (4%). 
ANTIBIOTIC ACTIVITY IN VlTRO AND IN VlVO 
Streptococcus pneumoniae 
Multidrug-resistant pneumococci were first identified 
in South Africa in 1977 [18]. In the early 1990s, 
resistance to penicillin G reached rates above 10% in 
many parts of the world and now exceeds 40% in 
France, the USA, Spain, Hungary, New Guinea, South 
Africa, Japan, Korea, Taiwan, Chile, Brazil and Mexico. 
Rates have continued to increase during the past 
decade, and aggregate rates of intermediate and high- 
level penicillin resistance have reached 50%) in some 
parts of western Europe 1191. By the year 2000, the 
global prevalence of penicillin-resistant Streptococcus 
pneirrnoniae is expected to reach 50%, with half of the 
strains manifesting high levels of penicillin resistance. 
Increased rates of resistance to non-p-lactam antibiotics 
are also expected [20]. 
Because of the incremental nature of pneumo- 
coccal resistance to penicillin G, consensus limits have 
been established to define susceptible and resistant 
strains: susceptible, MIC 50.06 mg/L; intermediate, 
0.12-1 mg/L; resistant, >1 mg/L (France), 2 2  mg/L 
(other countries). In contrast to ampicillin, which has 
MICs similar to those of penicillin G, amoxycillin has 
better activity against penicillin-resistant Streptococcus 
pneumoniae (Table 2). Penicillin-resistant strains are also 
resistant to oral cephalosporins. All oral cephalosporins 
are less active than penicillin G or amoxycillin against 
intermediate and resistant strains. 
In recent studies, it has been shown that 230%) 
of penicillin-resistant Streptococcus pneumoniae isolates 
are also resistant to erythromycin A. For example, 
in the USA, approximately 20-259'6 of intermediate- 
resistant isolates and >50% of resistant strains are 
erythromycin A resistant. Erythromycin A-resistant 
Streptococcus pneumoniae was uniformly cross-resistant 
with other available 14- or 15-membered ring macro- 
lides. However, it has been recorded in France that 
18% of Streptococcus pneumoniae strains susceptible to 
penicillin G are resistant to erythromycin A 16,211. This 
phenomenon also occurs in Greece and Italy. 
High rates of resistance to co-trimoxazole (25- 
50%) among Streptococcus pnenmoniae isolates have been 
found in some European countries such as Spain, with 
lower rates in Switzerland, Italy and Sweden (110%). 
Resistance to co-trimoxazole is strongly associated 
with resistance to penicillin G [23]. Rates of resistance 
to tetracyclines, although decreasing during the past 
few years, remain high (>25%) in Spain, France and 
Italy, with lower rates in other European countries. In 
Spain, chloramphenicol resistance has slowly decreased 
from 60% in 1981 to 27% in 1992. Goldstein et a1 
showed that resistance rates to non-0-lactams are 
significantly higher in penicillin-resistant isolates com- 
pared with penicillin-susceptible isolates 161. The 
activity of fluoroquinolones is independent of the 
resistance pattern to 0-lactam antibiotics. The in vitro 
activity of numerous compounds has been tested 
against isolates with different resistance patterns to 
penicillin G (Table 2) [21]. In France, more than 60% 
of multidrug-resistant Streptococcus pneumoniae isolates 
are resistant to erythromycin A. MICso values are thus 
higher ( 1  6-32 mg/L) than those usually recorded 
(MICio, 0.06-0.1 2 mg/L) [24]. 
Fluoroquinolones 
Currently available fluoroquinolones such as cipro- 
floxacin and ofloxacin are considered as having only 
moderate activity against Streptococcus pneumoniae. 
New fluoroquinolone derivatives such as sparfloxacin, 
levofloxacin, trovafloxacin and grepafloxacin display 
good antipneumococcal activity (Table 3). Trovafloxacin 
has been shown to be more active than temafloxacin 
and ciprofloxacin against acute pneumococcal infections, 
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Table 2 In vitro activity of some oral antibiotics against Streptococcus pneumoniae [21,223 
MIC (nig/L) 
Pen-S Pen-I Pen-R 
50% 90% 50% 90% 50% 90% 
Penicillin G 
Cefuroxime 
Cefaclor 
Cefixime 
Cefprozil 
Loracarbef 
Amoxycillin 
Co-amoxiclav 
Erythromycin A 
Clarithromycin 
Azithromycin 
Clindamycin 
Co-trimoxazole 
0.015 
0.03 
0.5 
0.25 
0.03 
1 .o 
0.01 
0.03 
50.06 
50.06 
S0.06 
50.06 
50.5 
0.03 
0.03 
1 .0 
0.25 
0.125 
2.0 
0.03 
0.03 
50.06 
20.06 
50.06 
50.06 
>8 
0.5 
0.5 
4.0 
4.0 
0.5 
4.0 
0.125 
0.125 
50.06 
20.06 
50.06 
50.06 
>8 
1.0 
4.0 
64 
32 
32 
4.0 
1 .0 
1 .0 
4 
2 
4.0 
S0.06 
>8 
2.0 
4.0 
64 
32 
232 
4.0 
1 .0 
1 .0 
50.06 
10.06 
50.06 
50.06 
>8 
4.0 
8.0 
128 
32 
16.0 
232 
2.0 
2.0 
>64 
> 64 
> 64 
> 64 
>8 
with PDsovalues of 1.3, 10.4 and >50 mg/kg respect- 
ively [32]. Wise et al showed that the susceptibility of 
Streptococcus pneumoniae isolates to fluoroquinolones 
could be divided into three subgroups (Table 4) [33]. 
Two strains were resistant to all the fluoroquinolones 
tested (group 3) and the data suggest that there is more 
than one mechanism of resistance to fluoroquinolones 
in this species. Resistant isolates are currently only 
rarely isolated in clinical practice, with a frequency of 
about 1% [24]. 
Table 3 In vitro activity of fluoroquinolones against 
Streptococcus pueumoniae isolates (Pen-S/I/R) [25-311 
MIC (mg/L) 
50% 90% 
Ciprofloxacin 
Ofloxacin 
Levofloxacin 
'Trovafloxacin 
Fleroxacin 
Spadoxacin 
Grepafloxacin 
Tosufloxacin 
2 2 
2 4 
1 1 
0.12 0.25 
8 16 
0.25 0.5 
0.25 0.25 
0.25 0.25 
Table 4 Streptococcus pneumoniae: three subgroups of 
susceptibility to fluoroquinolones 
MIC (mg/L) 
Ciprofloxacin Trovafloxacin 
Group 1 0.5-1 0.12-0.25 
Group 2 4-8 0.12-0.25 
Group 3 64-128 4-8 
Adapted from Wise et al [33]. 
Animal models 
Azoulay-Dupuis et a1 demonstrated that two types of 
fluoroquinolones can be distinguished: those with poor 
(ciprofloxacin, ofloxacin) and those with significant 
(temafloxacin) antipneumococcal activity [34]. They 
used two murine models (acute pneumonia (Swiss 
mice) and subacute pneumonia (C57B1/6 mice)), and 
compared the in vivo activity of amoxycillin, erythro- 
mycin A, ofloxacin, ciprofloxacin and temafloxacin. 
In the acute model, rapid bacterial growth required 
treatment before 18 h to be successful. At a dose of 
50 mg/kg, amoxycillin showed the greatest bactericidal 
activity (100% survival). At this dose, temafloxacin was 
less active (79% survival), and 85% survival was reached 
at 75 mg/kg. To achieve the same rate of survival with 
ofloxacin, 250 mg/kg was needed and 100% survival 
was achieved at 250 mg/kg ciprofloxacin. 
In the subacute model, treatment could be initiated 
at times varying from 18 to 96 h postinfection, during 
which progressive lung alterations and continuous 
increases in bacterial counts occurred. The model 
mimicked the pathogenesis of most cases of human 
bacterial pneumonia. Ofloxacin and ciprofloxacin were 
active when given at an early stage of infection and at 
high doses (100 mg/kg). Starting 48 h postinfection, 
both compounds were inactive, whereas temafloxacin 
was active until the latest stages of the disease. 
In the acute model, no drop in pneumococcal 
counts in lung tissue was obtained with ofloxacin or 
ciprofloxacin even after six doses. With temafloxacin, 
sterilization of the lung and blood were obtained 
after four doses, and with amoxycillin after two 
doses. Similar results were obtained with sparfloxacin 
P I .  
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In a study by Klesel et al, NMRI  mice were 
challenged intraperitoneally with Streptococcus pneu- 
moniae 1 147 (penicillin-susceptible strain) [36]. In 
niouse protection tests, levofloxacin, ofloxacin and 
ciprofloxacin were administered orally inimediately 
and 4 h after infection. Levofloxacin displayed some 
activity (ED50 of 76.24 mg/kg), whereas ofloxacin and 
ciprofloxacin were inactive (> lo0  mg/kg). In time 
kill curve studies, NMRI  mice with experimental 
pneumonia produced with Streptococcus pneumoniae 
1147 were treated with 50 mg/kg of fluoroquinolone 
1 h after bacterial challenge. Blood cultures and colony 
counts in the lungs were done at intervals between 
1 and 48 h after therapy. Viable Streptococcus pneuvnoniae 
declined by 2.6 loglo CFU/g lung during the first 
6 h of treatment with levofloxacin but only by 1.3 
logio CFU and 0.20 log10 CFU after treatment with 
ofloxacin and ciprofloxacin, respectively. Eighteen 
hours later, the number of viable bacteria in the lungs 
after treatment with levofloxacin was 5 loglo CFU/g 
lower than in the control animals. With ofloxacin 
bacterial counts were 3 loglo CFU/g lower than those 
of the control. Treatment with ciprofloxacin led to an 
initial reduction in viable bacteria but thereafter viable 
counts were only 1 loglo CFU/g lower than those of 
the control animals. Blood cultures from each of the 
animals treated with levofloxacin for 24 h were sterile, 
whereas all blood cultures from controls or in animals 
treated with ciprofloxacin and ofloxacin yielded growth. 
Haemophilus influenzae 
H. i@uenzae is an increasingly common cause of CAP 
in adults, partly attributable to growing recognition 
of the infection, based on improved bacteriologic 
techniques and more frequent use of invasive diagnostic 
procedures. The increase may also be a result of the 
growing number of patients with human immuno- 
deficiency virus (HIV) disease, who are more suscep- 
tible to serious infections caused by H .  inzuenzne. 
Before the early 1970s, when [3-lactamase-mediated 
ampicillin resistance in H .  injuenzae was first reported, 
this important respiratory pathogen was uniformly 
susceptible to ampicillin. During the past two decades, 
however, the overall pattern of H. influenzae resistance 
has shifted and the prevalence of p-lactamase pro- 
duction in non-typeable strains of H .  inzuenzae has 
increased dramatically 1371. Two other resistance 
mechanisms in non-typeable strains are altered 
penicillin-binding-proteins, arid diminished membrane 
perrneabihty. p-Lactaniase-independent anninopenicdlin 
resistance in H. influenzae (non-typeable strains) remains 
below 5% in the USA and in western Europe [38,39]. 
However, the incidence of such clinical isolates could 
be underestimated, since they grow poorly on H T M  
media, and in many cases, growth is extremely sensitive 
to the quality and freshness of the medium. 
Macrolides have only borderline in vitro activity 
against H. irzfiuenzae, with MIC values overlapping the 
susceptible breakpoints. However, high-level acquired 
resistance to macrolides has not yet been described. 
Current rates of tetracycline resistance in most western 
countries remain below 1096, although a higher rate of 
up to 15% has been reported in Spain. Co-triinoxazole 
resistance ranges from less than 5% (USA) to up to 15% 
(European countries), with a rate of 50-60% recorded 
in Spain. Rates of resistance among other oral anti- 
biotics remain low; among p-lactani antibiotics, oral 
cephalosporins (cefixime, cefpodoxime, cefuroxime, 
etc.) and co-amoxiclav are almost uniformly active 
against H. it$uenzae, with resistance rates below 1%. 
However, MICso/so values of oral cephenis against 
H .  iy’luenzae isolates resistant to anipicillin by a non- 
enzymatic mechanism are higher than those recorded 
against H. irzfiuenzae strains producing p-lactamases. 
In a recent national surveillance study in the USA, 
involving 1537 isolates of H .  injuenzae, 36.4% of 
the isolates were found to produce P-lactamases [39]. 
Thirty-nine strains were ampicillin intermediate- 
resistant or resistant, and 17 P-lactamase-producing 
strains were also resistant to co-anioxiclav (MIC modal: 
8 mg/L). Modal MICs for oral cephems are higher than 
those for P-lactamase-producing strains. Another USA 
survey of H. ir$uenzae susceptibility found that, among 
2278 clinical isolates, the overall rate of [3-lactamase 
production and ampicillin resistance was 36% [4O]. 
Non-P-lactamase mechanisms of resistance to ampicillin 
were rare (0.2%) and were attributable to altered 
penicillin-binding proteins. 
Chloramphenicol resistance occurs in H. irtflirenzae 
and, like ampicillin resistance, is primarily plasmid 
mediated. Non-enzymatic, chromosomally mediated 
chloramphenicol resistance has also been described. 
Trimethoprim resistance is chromosomally mediated. 
Fluoroquinolones are very effective against H .  irfhenzae, 
irrespective of the pattern of susceptibility to ampicillin 
(Table 5). 
Moraxella catarrhalis 
L\/loraxella cutarrlzalis is a normal inhabitant of the 
oropharynx which is rarely involved in CAP but is, to 
a greater extent, in acute sinusitis or otitis media [43]. 
Before the 1970s, the majority of clinical isolates of 
1Vlovaxella catarrhalis were susceptible to penicillin G and 
amoxycillin. During the early 1970s, the susceptibility 
pattern began to change and, by the late 198Os, more 
than 80% of clinical isolates were found to produce 
a chromosomal, constitutively produced P-lactamase. 
In the 1990s, more than 90% of the isolates are 
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Table 5 In vitro activity of fluoroquinolones against H. intuenzae [30,41,42] 
MIC (mg/L) 
Amp-s Amp-R p+ Amp-R p- 
50% 90% 50% 90% 50% 90% 
Levofloxacin 
Ofloxacin 
Ciprofloxacin 
Sparfloxacin 
Trovafloxacin 
Tosufloxacin 
Grepafloxacin 
Fleroxacin 
0.015 
0.025 
0.013 
0.013 
0.01 
10.006 
10.006 
0.03 
0.03 
0.05 
0.025 
0.025 
0.01 
0.013 
0.013 
0.06 
0.015 
0.025 
0.013 
0.013 
0.01 
10.006 
10.006 
0.03 
0.03 
0.05 
0.025 
0.025 
0.01 
0.013 
0.013 
0.06 
0.015 
0.025 
0.013 
0.013 
0.01 
10.006 
10.013 
0.03 
0.03 
0.05 
0.025 
0.025 
0.01 
0.013 
0.06 
0.06 
resistant to amoxycillin in many countries [24]. The 
enzymes BRO-1 and BRO-2 are transposon mediated, 
explaining their rapid spread. Low p-lactam MICs are 
still found, despite p-lactamase production (Table 6). 
Moraxella catarrhalis remains susceptible to oral cephems, 
co-amoxiclav, macrolides, tetracyclines and fluoro- 
quinolones. 
Low-level macrolide resistance (MIC >0.5 mg/L) 
is expressed by less than 5% of Moraxella catarrhalis strains 
and hgh-level (MIC >8 mg/L) resistance remains rare 
in Europe and the USA [45,46]. In a recent survey, 18% 
of clinical isolates from the respiratory tract were 
resistant (low level) to erythromycin A [47]. 
Tetracycline resistance remains low (< 3%) (enlux- 
tet B) in most Western countries, although local 
epidemics with resistant strains were reported in 1988 
in The Netherlands and China. Resistance to co- 
trimoxazole remains below 7% overall, but higher 
incidences have been reported in Spain and New 
Zealand [48]. Resistance to co-trimoxazole is due to 
acquired resistance to sulfonamides. Moraxella catarrhalis 
is naturally resistant to trimethoprim. Table 6 shows 
the in vitro activity of oral antibiotics against Moraxella 
catarrhalis [44]. 
Chlamydia pneumoniae 
Chlamydiae are obligate intracellular parasites with a 
unique development cycle. Data on the in vitro suscep- 
tibility of Chlamydia pneumoniae are limited, in part 
because of the small number of clinical isolates available 
for testing. The methods used for the susceptibility 
testing of Chlamydiapneumoniae are not yet standardized, 
and there are discrepancies between the results obtained 
by different laboratories [49]. Only antibacterial agents 
concentrated within cells, such as the fluoroquinolones. 
are active against Chlamydia pneumoniae. Erythromycin 
A and doxycycline are considered the treatment of 
choice. Hammerschlag has reviewed the antibacterial 
activities of different compounds against Chlamydia 
pneumoniae (Table 7) [50]. 
Mycoplasma pneumoniae 
Mycoplasma pneumoniae is an important cause of RTIs. 
Tetracyclines and macrolides are the two groups of 
antibiotics commonly used for the treatment of myco- 
plasma infections, and occasional resistance has been 
reported. The in vitro activity of oral antibiotics against 
Mycoplasrna pneumoniae is summarized in Table 8. 
The in vitro activity of fluoroquinolones is variable. 
Levofloxacin (MICso,90, 0.5/1 mg/L) is twice as active 
as ofloxacin (MICso/90, 1 mg/L) and doxycycline 
is more active than both these agents (MIcso/90, 
0.1-1 mg/L) [51]. Grepafloxacin and sparfloxacin 
Table 6 In vitro activity of some oral antibiotics against 
Moraxella catarrhalis 
MIC (mg/L) 
50% 90% 
Penicillin G 
Amoxycillin 
Co-amoxiclav 
Cefaclor 
Cefuroxime 
Cefixime 
Erythromycin A 
Clarithromycin 
Azithromycin 
Ciprofloxacin 
Levofloxacin 
Sparfloxacm 
Trovafloxacin 
Grepafloxacin 
Tosufloxacin 
Ofloxacin 
Co-trimoxazole 
2 
0.5 
0.06 
0.5 
1 
0.12 
0.12 
0.06 
0.03 
0.03 
0.06 
0.01 
0.03 
0.03 
0.015 
0.12 
0.5 
16 
4 
0.25 
1 
2 
0.5 
0.13 
0.13 
0.03 
0.06 
0.06 
0.03 
0.06 
0.06 
0.03 
0.12 
0.5 
Adapted from Berk et a1 [44]. 
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Table 7 In vitro activity of antibacterials against Chlamydia 
pneumoniae 
Table 9 In vitro susceptibility of Lcgtonella pneumoplzrla 
157,581 
Tctracycline 
Doxycycline 
Minocycline 
Erythromycin A 
Azithromycm 
Clarithromycin 
Ciprofloxacin 
Ofloxacin 
Levofloxacin 
Fleroxacin 
Sparfloxacin 
Grepafloxacin 
MIC (mg/L) 
0.0.5-1 2 
0.06-0.5 
0.015 
0.01-1 
0.06-1 
0.007-0.25 
0.25-4 
0.1 25-0.5 
2-8 
0.5-2 
0.06-0.25 
0.06-0.5 
MCC (rng/L) 
0.05-4 
0.125-0.25 
0.01 - >1 
0.125-2 
0.008-1 
0.25->16 
0.5-2 
0.125-0.25 
2-8 
0.06->2 
0.03-0.5 
- 
MIC (nig/L) 
.5iW on%, 
Erythromycin A 1 2 
Clarithromycin 0.12 0.25 
Azithromycm 0.5 2 
Ciprofloxacin O.O(J8 0.008 
Ofloxacin 0.01.5 0.015 
Levofloxacin 0.008 0.008 
Trovafloxacin 1o.oi1.1 10.004 
Sparfloxacin 0.002 0.002 
Kange of activities adapted from Hanunerschlag (501. 
Table 8 In vitro activity of oral antibiotics against 
Mycoplarma pneumonrar [51-561 
50% 90% 
Erythromycin A 
Clarrthroniycin 
Azithromycm 
Ofloxacin 
Levofloxacin 
Ciprofloxacin 
Sparfloxacin 
Fleroxacin 
Grepafloxacin 
Trovafloxacin 
1)oxycycline 
Tetracycline 
1 0.0 1 5 
10.004 
0.002 
1 
0.5 
2.0 
0.125 
3 
0.125 
0.25 
0 1 
1 
<0.015 
50.004 
0.002 
1 
1 
2.0 
0.25 
4 
0.25 
0.25 
0.2 
1 
display the same activity (MICso/go, 0.125/0.25 mg/L) 
and temafloxacin is less active (MICso/90, 1 mg/L) [52]. 
Lomefloxacin and fleroxacin are poorly active and 
ciprofloxacin is slightly less active than ofloxacin [53]. 
Standardization of susceptibility testing of Mycoplarma 
pnerrrnoniae is difficult because of the slow growth of the 
organism, and variations due to the incubation period 
have been recorded, especially with macrolides. 
Legionella pneumophila 
Only compounds which achieve a sufficient intra- 
cellular concentration show good activity against 
L. pneumophila. In vitro, fluoroquinolones are very active 
against Legionellu species (Table 9). In BCYE medium, 
the charcoal in the test media has an inhibitory effect, 
especially evident with fluoroquinolones (92%) and 
rifampicin (90.5%). Thus, MICs have to be corrected 
for the bound fraction. Levofloxacin, ofloxacin and 
ciprofloxacin are more active against intracellular 
L. pneumopkila than erythromycin A, which is only 
inhibitory in macrophage systems, even at concen- 
trations as high as 5 mg/L. In contrast, most fluoro- 
quinolones tend to be bactericidal against L. pnenrnophila 
in macrophages. Ofloxacin, ciprofloxacin and levo- 
floxacin are all bactericidal at 1 mg/L. In addition, a 
relatively long period is required for regrowth of 
L. pneirmophila after removal of the compounds, except 
with erythromycin A. In a guinea pig model, ofloxacin 
is more active than ciprofloxacin and erythromycin A, 
while levofloxacin and ofloxacin show equivalent 
activity [59,60]. 
BACTERICIDAL ACTIVITY 
Streptococcus pneumoniae 
In comparison to penicillin-susceptible strains, a s ign -  
ficantly higher number of penicillin-resistant Strepto- 
coccus pneumoniae strains are tolerant to penicillin G 
1611. Amoxycillin, in contrast to cephalosporins (in- 
cluding cefotaxime), has good bactericidal activity 
[62]. Erythromycin A is bactericidal within 24 h at 
2 2  x MIC against susceptible strains. Dalfopristid 
quinupristin has a more rapid bactericidal activity, and 
remains active against erythromycin-resistant strains 
All fluoroquinolones present a paradoxical effect 
with an optimum bactericidal concentration (OBC). 
For this reason, the bactericidal activity must be tested 
at  various concentrations to allow an accurate com- 
parison of compounds. Several comparative parameters 
have been proposed, one of which, the bactericidal 
index, takes into account serum pharniacokinetics 
[25,64] and is calculated as the sum of percentage kill 
obtained up to the drug peak concentration. All the 
fluoroquinolones have a similar bactericidal profile, 
with an OBC at 3-5 mg/L which corresponds to 
the highest serum level for most compounds. As a 
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consequence, the more active a fluoroquinolone is (low 
MIC), the greater is its bactericidal activity, as long 
as the peak serum level is 23 mg/L. Hence, the 
bactericidal index of levofloxacin is much higher than 
those of ofloxacin, ciprofloxacin and sparfloxacin. 
In a study by Baquero et al, levofloxacin was 
compared to ofloxacin and sparfloxacin against peni- 
cillin-susceptible, intermediate-susceptible and resistant 
strains at two different inocula by the killing-curve 
technique at 4 x MIC [25]. Levofloxacin was always the 
most active compound. In general, the activity of the 
fluoroquinolones was lower at lo6 CFU/mL and they 
were more effective against penicillin-resistant strains. 
Comparative kill kinetics of levofloxacin, sparfloxacin, 
ciprofloxacin and D U  6859a were determined against 
nine isolates of Streptococcus pneurnoniae with different 
patterns of resistance to penicillin G (three of each 
phenotype) [65]. At 8 XMIC, bactericidal activity was 
reached after 6, 12, 12 and 24 h of contact for D U  
6859a, levofloxacin, ciprofloxacin and sparfloxacin, 
respectively. However, the MIC value and the pharma- 
cokinetic profile of each compound have to be taken 
into account. 
Exposure of a penicillin-resistant strain of Strepto- 
coccus pneumoniae (levofloxacin MIC, 0.5 mg/L) to 
pharmacokinetic concentrations of levofloxacin follow- 
ing a single oral 500-mg dose rapidly reduces the initial 
inoculum by 3 loglo. If a second 500-mg dose follows 
after 12 h, killing proceeds. For an isolate with an 
MIC of 2mg/L for levofloxacin, a reduction of 
2 loglo was obtained, but regrowth was recorded. A 
second dose 12 h after first dosing provided additional 
killing [66]. 
Haemophilus influenzae and Moraxella catarrhalis 
The bactericidal activities of sparfloxacin, ciprofloxacin, 
co-trimoxazole, co-amoxiclav and erythromycin A 
were studied by killing curves at 4 x MIC against one 
strain of H. infuenzae and one strain of Moraxella 
catarrhalis [67]. The fluoroquinolones had the best 
bactericidal activity against both H .  irguenzae and 
Moraxella catarrhalis, followed by co-amoxiclav and 
erythromycin A, with co-trimoxazole being the least 
active. In another study, the bactericidal activities 
of azithromycin, erythromycin A and roxithromycin 
were determined against 70 H. inzuenzae isolates, 
including 13 p-lactamase producers [68]. Kill kinetics 
demonstrated that azithromycin was the most rapidly 
bactericidal macrolide when tested at 2 x MIC. After 
4 h of incubation, 99.9% killing was obtained for 59% 
and 99% of the strains at  1 and 4 mg/L, respectively, i.e. 
1-2 x MIC and 4-8 x MIC. The pharmacokinetics of 
azithromycin indicate that this macrolide could display 
good bactericidal activity in vivo. 
POST-ANTIBIOTIC EFFECT (PAE) 
The PAE is a particularly interesting feature, observed 
mainly with fluoroquinolones and macrolides or related 
compounds. Although the clinical relevance of the PAE 
is not established, it may lengthen the duration of 
activity of an antibiotic when the serum (or tissue) level 
has decreased below the MIC. 
In a study by Odenholt-Tornqvist et al, one strain 
of Streptococcus pneumoniae was exposed to sparfloxacin 
and roxithromycin at 10 XMIC for 2 h and then 
exposed to a subinhibitory concentration of 0.1-0.3 x 
MIC (sub-MIC effect, SME) [69]. The PAEs of 
sparfloxacin and roxithromycin were 2.5 and >7.8 h, 
respectively. At 0.1 x MIC, the PAEs increased to 3.1 
and >7.8 h, respectively. At 0.2 and 0.3 x MICs, the 
PAE of sparfloxacin increased to 3.8 and 6.0 h, 
respectively. In another study, the PAE of penicillin G 
at 10 X MIC and the PAE-SME against Streptococcus 
pneumoniae were studied [70]. The PAE was 1-5 h and 
the PAE-SME increased up to 3.5 h at 0.3 x MIC and 
was 4.6 to >20 h for 0.5 x MIC. These data are in 
contrast with those from other studies claiming that 
p-lactams (except imipenem) have no PAEs against 
Streptococcus pneumoniae. The PAEs of sparfloxacin 
and ciprofloxacin against one strain of Streptococcus 
pneumoniae (penicillin-resistant), H. infuenzae and 
Moraxella catarrhalis at 1 and 4 x MIC were studied by 
Speciale et al (results summarized in Table 10) [67]. In 
another study, one strain of Streptococcus pneumoniae 
was exposed to erythromycin A and roxithromycin 
[71]. The PAEs found were 0.8-1.4 and 0.6-1.6 h, 
respectively. The PAEs of ofloxacin, levofloxacin and 
sparfloxacin against one isolate of penicillin-resistant 
Streptococcus pneumoniae (MIC, 4 mg/L) were studied 
[48]. At 2 and 4 x MIC, the PAEs of ofloxacin and 
levofloxacin were very similar, 1.5-2 h while the PAE 
of sparfloxacin was lower, about 1 h. 
Table 10 PAE (hours) of spadoxacin and ciprofloxacin 
against respiratory pathogens [67] 
Sparfloxacin Cipmfloxacin 
lXMIC 4XMIC IXMIC 4XMIC 
Streptococcus pneumoniae 1.1-1.5 1.2-1.7 1 .l-1.5 1.2-1.6 
Moraxella catarrhalis 1.6-2.2 1.9-2.6 1.6-2.2 1.9-2.4 
H .  influenzae 1.9-2.2 2.0-2.5 1.9-2.1 2.1-2.5 
CONCLUSIONS 
During the last few decades, the emergence of newly 
recognized pathogens and the increasing number of 
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patients with serious underlying diseases have altered 
the etiology of RTIs. Atypical microorganisms 
(kgionella spp., Chlamydia pneumoniae, Mycoplasma pneu- 
moniae) often exceed 10% of the recorded pathogens, 
and these data may even be an underestimate since, in 
about 50% of the patients, no etiologic agent can be 
identified. Resistance of Streptococcus pneumoniae to 
p-lactams and other available antibacterials emphasizes 
the need for alternative drugs. Older fluoroquinolones, 
due to their poor antipneumococcal activity, should not 
be considered as first-line therapeutic agents in RTIs. 
The introduction in clinical practice of newer fluoro- 
quinolone agents, such as levofloxacin and trovafloxacin, 
which combine good activity against pneumococci and 
atypical organisms in vitro and in animal models as well 
as in clinical trials, will open the field of respiratory 
fluoroquinolones. 
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